Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion)

Christopher M Reid, Elsdon Storey, Tien Y Wong, Robyn Woods, Andrew Tonkin, Jie Jin Wang, Anthony Kam, Andrew Janke, Rowan Essex, Walter P Abhayaratna, Marc M Budge, ASPREE Study Group, Christopher M Reid, Elsdon Storey, Tien Y Wong, Robyn Woods, Andrew Tonkin, Jie Jin Wang, Anthony Kam, Andrew Janke, Rowan Essex, Walter P Abhayaratna, Marc M Budge, ASPREE Study Group

Abstract

Background: This paper describes the rationale and design of the ENVIS-ion Study, which aims to determine whether low-dose aspirin reduces the development of white matter hyper-intense (WMH) lesions and silent brain infarction (SBI). Additional aims include determining whether a) changes in retinal vascular imaging (RVI) parameters parallel changes in brain magnetic resonance imaging (MRI); b) changes in RVI parameters are observed with aspirin therapy; c) baseline cognitive function correlates with MRI and RVI parameters; d) changes in cognitive function correlate with changes in brain MRI and RVI and e) whether factors such as age, gender or blood pressure influence the above associations.

Methods/design: Double-blind, placebo-controlled trial of three years duration set in two Australian academic medical centre outpatient clinics. This study will enrol 600 adults aged 70 years and over with normal cognitive function and without overt cardiovascular disease. Subjects will undergo cognitive testing, brain MRI and RVI at baseline and after 3 years of study treatment. All subjects will be recruited from a 19,000-patient clinical outcome trial conducted in Australia and the United States that will evaluate the effects of aspirin in maintaining disability-free longevity over 5 years. The intervention will be aspirin 100 mg daily versus matching placebo, randomized on a 1:1 basis.

Discussion: This study will improve understanding of the mechanisms at the level of brain and vascular structure that underlie the effects of aspirin on cognitive function. Given the limited access and high cost of MRI, RVI may prove useful as a tool for the identification of individuals at high risk for the development of cerebrovascular disease and cognitive decline.

Trial registration: clinicaltrials.gov Identifier: NCT01038583.

Figures

Figure 1
Figure 1
Retinal Vascular Imaging measurement of Retinal Calibre.

References

    1. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K. et al.National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer's Disease and Cognitive Decline. NIH State-of-the-Science Conference Statement. 2010;27(4):1–30.
    1. Van Hooren SAH, Valentijn AM, Bosma H, Ponds RWHM, Van Boxtel MPJ, Jolles J. Cognitive functioning in healthy older adults aged 64-81: A cohort study into the effects of age, sex, and education. Aging, Neuropsychology, and Cognition. 2007;14(1):40–54. doi: 10.1080/138255890969483.
    1. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Annals of Neurology. 2006;60(6):688–695. doi: 10.1002/ana.21031.
    1. Hsiung GYR, Donald A, Grand J, Black SE, Bouchard RW, Gauthier SG, Loy-English I, Hogan DB, Kertesz A, Rockwood K. et al.Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. Dementia and Geriatric Cognitive Disorders. 2006;22(5-6):413–420. doi: 10.1159/000095751.
    1. Piguet O, Grayson DA, Creasey H, Bennett HP, Brooks WS, Waite LM, Broe GA. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology. 2003;22(3):165–171. doi: 10.1159/000069886.
    1. Ince PG. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357(9251):169–175.
    1. Clarke R, Joachim C, Esiri M, Morris J, Bungay H, Molyneux A, Budge M, Frost C, King E, Barnetson L, Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia. 2000. pp. 497–500.
    1. Shepherd CE, Piguet O, Broe GA, Creasey H, Waite LM, Brooks WS, Kril JJ. Histocompatibility antigens, aspirin use and cognitive performance in non-demented elderly subjects. Journal of Neuroimmunology. 2004;148(1-2):178–182. doi: 10.1016/j.jneuroim.2003.11.007.
    1. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. British Medical Journal. 2007;334(7601):987–990. doi: 10.1136/.
    1. Fujita S, Kawaguchi T, Uehara T, Fukushima K. Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. International Psychogeriatrics. 2005;17(4):689–698. doi: 10.1017/S104161020500164X.
    1. Antithrombotic Trialists C. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678):1849–1860. doi: 10.1016/S0140-6736(09)60503-1.
    1. Bracco L, Piccini C, Moretti M, Mascalchi M, Sforza A, Nacmias B, Cellini E, Bagnoli S, Sorbi S. Alzheimer's disease: Role of size and location of white matter changes in determining cognitive deficits. Dementia and Geriatric Cognitive Disorders. 2005;20(6):358–366. doi: 10.1159/000088562.
    1. Sato H, Koretsune Y, Fukunami M, Kodama K, Yamada Y, Fujii K, Kitagawa K, Hori M. Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation. Circulation Journal. 2004;68(5):410–416. doi: 10.1253/circj.68.410.
    1. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2003;34(2):392–396. doi: 10.1161/01.STR.0000052631.98405.15.
    1. Ryan CM, Geckle MO, Orchard TJ. Cognitive efficiency declines over time in adults with Type 1 diabetes: Effects of micro- and macrovascular complications. Diabetologia. 2003;46(7):940–948. doi: 10.1007/s00125-003-1128-2.
    1. Wong TY. Is retinal photography useful in the measurement of stroke risk? Lancet Neurology. 2004;3(3):179–183. doi: 10.1016/S1474-4422(04)00682-9.
    1. Wong T, Mitchell P. The eye in hypertension. Lancet. 2007;369(9559):425–435. doi: 10.1016/S0140-6736(07)60198-6.
    1. Schneider R, Rademacher M, Wolf S. Lacunar infarcts and white matter attenuation: Ophthalmologic and microcirculatory aspects of the pathophysiology. Stroke. 1993;24(12):1874–1879. doi: 10.1161/01.STR.24.12.1874.
    1. Cooper LS, Wong TY, Klein R, Sharrett AR, Bryan RN, Hubbard LD, Couper DJ, Heiss G, Sorlie PD. Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: The atherosclerosis risk in communities study. Stroke. 2006;37(1):82–86.
    1. Ding J, Patton N, Deary IJ, Strachan MWJ, Fowkes FGR, Mitchell RJ, Price JF. Retinal microvascular abnormalities and cognitive dysfunction: A systematic review. British Journal of Ophthalmology. 2008;92(8):1017–1025. doi: 10.1136/bjo.2008.141994.
    1. Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ, Mosley TH, Klein BEK, Hubbard LD, Szklo M. Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: The Atherosclerosis Risk in Communities Study. Stroke. 2002;33(6):1487–1492. doi: 10.1161/01.STR.0000016789.56668.43.
    1. Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR, Sharrett AR. Retinal microvascular abnormalities and incident stroke: The Atherosclerosis Risk in Communities Study. Lancet. 2001;358(9288):1134–1140. doi: 10.1016/S0140-6736(01)06253-5.
    1. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BEK, Hubbard LD. Retinal arteriolar narrowing and risk of coronary heart disease in men and women: The Atherosclerosis Risk in Communities Study. Journal of the American Medical Association. 2002;287(9):1153–1159. doi: 10.1001/jama.287.9.1153.
    1. Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MMB, De Jong PTVM. Retinal vessel diameters and cerebral small vessel disease: The Rotterdam Scan Study. Brain. 2006;129(1):182–188.
    1. Kwa VIH, Van der Sande JJ, Stam J, Tijmes N, Vrooland JL. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology. 2002;59(10):1536–1540.
    1. May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: A review of long-term trials. Progress in Cardiovascular Diseases. 1982;24(4):331–352. doi: 10.1016/0033-0620(82)90010-X.
    1. Troche CJ, Tacke J, Hinzpeter B, Danner R, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. European Heart Journal. 1998;19(SUPPL C):C59–C65.
    1. Katz S, Akpom CA. A measure of primary sociobiological functions. International Journal of Health Services. 1976;6(3):493–508. doi: 10.2190/UURL-2RYU-WRYD-EY3K.
    1. Teng EL, Chui HC. The Modified Mini-Mental State (MMS) examination. Journal of Clinical Psychiatry. 1987;48(8):314–318.
    1. Ruff RM, Light RH, Parker SB, Levin HS. Benton controlled Oral Word Association Test: Reliability and updated norms. Archives of Clinical Neuropsychology. 1996;11(4):329–338.
    1. Brandt J, Benedict R. Hopkins verbal learning test - revised. Inc PAR. Lutz, Fla; 2001.
    1. Strauss E, Sherman M, Spreen O. A compendium of Neuropsychological Tests. 3. New York: Oxford University Press; 2006.
    1. Radloff LS, Teri L. Use of the Center for Epidemiological Studies-Depression Scale with older adults. Clinical Gerontologist. 1986;5(1-2):119–136.
    1. Pohjasvaara T, Leskelä M, Vataja R, Kalska H, Ylikoski R, Hietanen M, Leppävuori A, Kaste M, Erkinjuntti T. Post-stroke depression, executive dysfunction and functional outcome. European Journal of Neurology. 2002;9(3):269–275. doi: 10.1046/j.1468-1331.2002.00396.x.
    1. Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology. 1935;18(6):643–662.
    1. D'Elia L. Color Trails Test: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1996.
    1. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission, Supplement. 2000. pp. 23–30.
    1. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN. et al.National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–2241. doi: 10.1161/01.STR.0000237236.88823.47.
    1. Evans AC. The NIH MRI study of normal brain development. NeuroImage. 2006;30(1):184–202. doi: 10.1016/j.neuroimage.2005.09.068.
    1. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, Davis MD, Cai J. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology. 1999;106(12):2269–2280. doi: 10.1016/S0161-6420(99)90525-0.
    1. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BEK. Revised formulas for summarizing retinal vessel diameters. Current Eye Research. 2003;27(3):143–149. doi: 10.1076/ceyr.27.3.143.16049.
    1. Verluis CE, van der Mast RC, van Buchem MA, Bollen ELEM, Blauw GJ, Eekhof JAH, van der Wee NJA, de Craen AJM, Shepherd J, Cobbe SM. et al.Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease. The PROSPER Study. International Journal of Geriatric Psychiatry. 2006;21(4):375–381. doi: 10.1002/gps.1477.
    1. Van Den Heuvel DMJ, Admiraal-Behloul F, Ten Dam VH, Olofsen H, Bollen ELEM, Murray HM, Blauw GJ, Westendorp RGJ, De Craen AJM, Van Buchem MA. Different progression rates for deep white matter hyperintensities in elderly men and women. Neurology. 2004;63(9):1699–1701.
    1. Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. Journal of Anatomy. 2005;206(4):319–348. doi: 10.1111/j.1469-7580.2005.00395.x.
    1. Bush TL, Riedel D. Screening for total cholesterol: Do the National Cholesterol Education Program's recommendations detect individuals at high risk of coronary heart disease? Circulation. 1991;83:1287–1293.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi